Schering's Proventil
Executive Summary
Switchovers to Repetabs formula of beta-agonist bronchodilator accounted for one-third of all Proventil tablet sales in 1988, not one-third of the asthma drug's total volume, as reported in the March 20 issue of "The Pink Sheet" (T&G-6). Repetabs sales represent about 6% of total $ 100 mil. Proventil sales. The product is a b.i.d. formulation. Proventil inhaler volume is roughly $ 59 mil., followed in order by $ 19 mil. for solution form, $ 13 mil. for tablets and roughly $ 3 mil. for Proventil syrup.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.